2-Brom-3'-cyano-propiophenon | 50916-36-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Brom-3'-cyano-propiophenon
• 英文别名: 3-(2-Bromopropanoyl)benzonitrile
• CAS: 50916-36-4
• 化学式: C₁₀H₈BrNO
• 分子量: 238.084
• InChiKey: WSZDGUHPPVFMAD-UHFFFAOYSA-N

物化性质

• 沸点：
  322.5±22.0 °C(Predicted)
• 密度：
  1.48±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  40.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-Brom-3'-cyano-propiophenon 在 双氧水 、 溶剂黄146 作用下， 反应 0.75h， 生成 5-(3-cyanophenyl)-4-methyl-1-(3-methylphenylamino)-1H-imdazole
  参考文献：
  名称：

  N-Aminoimidazole Derivatives Inhibiting Retroviral Replication via a Yet Unidentified Mode of Action

  摘要：

  The synthesis of a series of N-aminoimidazoles (NAIMs) with an uncommon spectrum of antiretroviral activity is described. From a group of 60 closely related molecules, we were able to subdivide the molecules in different groups based on their anti-HIV and anti-SIV activity in vitro (i) molecules acting on a new, immediate postintegration step, (ii) molecules acting on both postintegration and HIV-1 reverse transcriptase (RT) as NNRTI, and (iii) molecules that mainly act at the HIV-1 RT according to an NNRTI-type mode of action.

  DOI：

  10.1021/jm0211117
• 作为产物：
  描述：

  3-硝基苯丙酮 在 盐酸 、 溴 、 tin(ll) chloride 作用下， 以 乙醚 、 溶剂黄146 为溶剂， 反应 2.0h， 生成 2-Brom-3'-cyano-propiophenon
  参考文献：
  名称：

  Pratesi; Grana; Villa, Farmaco, Edizione Scientifica, 1973, vol. 28, # 10, p. 753 - 765

  摘要：

  DOI：

文献信息

• [EN] CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE LA CÉRAMIDE GALACTOSYLTRANSFÉRASE POUR LE TRAITEMENT DE MALADIES
  申请人：BIOMARIN PHARM INC

  公开号：WO2017214505A1

  公开（公告）日：2017-12-14

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

  本文描述了化合物、制备这种化合物的方法、含有这种化合物的药物组合物和药物、以及使用这种化合物治疗或预防与酶神经鞘糖脂转移酶（CGT）相关的疾病或紊乱的方法，例如溶酶体贮积症。溶酶体贮积症的例子包括 Krabbe 病和白质变性白血病。
• Hiv inhibiting n-aminoimidazole derivatives
  申请人：——

  公开号：US20040122024A1

  公开（公告）日：2004-06-24

  An N-aminoimidazole or N-aminoimidazolethione derivative, a pharmaceutically acceptable salt, a tautomer, an isomer, an ester or glycosylation product thereof, said derivative being represented by general formula (I): wherein m=zero or 1, n=zero or 1, R 1 is selected from hydrogen, methyl or ethyl, R 2 is selected from hydrogen, SH or —SR 0 wherein R 0 is methyl, benzyl or glucose residue; Q is selected from 1-naphtyl, 2-naphtyl, biphenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, thienyl, or a substituted or unsubstituted phenyl ring, wherein the substitution is understood as being one or two substituents selected from H, F, Cl, Br, I, methyl, ethyl or isopropyl; L is selected from 1-naphtyl, 2-naphtyl, biphenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, thienyl, or a substituted or unsubstituted phenyl ring wherein the substitution is understood as being one or two substituents selected from H, F, Cl, Br, I, methyl, ethyl or isopropyl. This invention further relates to the use of compounds of formula (I) as agents having biological activity, especially against viral infections.

  一种N-氨基咪唑或N-氨基咪唑硫醇衍生物，其药学上可接受的盐，互变异构体，异构体，酯或糖基化产物，所述衍生物由通式（I）表示： 其中m=0或1，n=0或1，R1选自氢，甲基或乙基，R2选自氢，SH或-SR0，其中R0为甲基，苄基或葡萄糖残基；Q选自1-萘基，2-萘基，联苯，2-吡啶基，3-吡啶基，4-吡啶基，2-嘧啶基，4-嘧啶基，5-嘧啶基，噻吩基或取代或未取代的苯环，其中取代被理解为是选择H，F，Cl，Br，I，甲基，乙基或异丙基中的一个或两个取代基；L选自1-萘基，2-萘基，联苯，2-吡啶基，3-吡啶基，4-吡啶基，2-嘧啶基，4-嘧啶基，5-嘧啶基，噻吩基或取代或未取代的苯环，其中取代被理解为是选择H，F，Cl，Br，I，甲基，乙基或异丙基中的一个或两个取代基。本发明还涉及将式（I）化合物作为具有生物活性的药物，特别是用于抗病毒感染。
• Imidazole guanidines, their preparation and compositions containing them
  申请人：Merck & Co., Inc.

  公开号：EP0020173A1

  公开（公告）日：1980-12-10

  Imidazole cyanoguanidines of formula where R1 is hydrogen or methyl; R2 is lower alkyl; each of m and n independently of the other, is 0, 1, 2 or 3; A is a phenylene, cyclohexylene, thienylene, tetrahydro- thienylene, or 1,3-dithianylene radical and is optionally substituted with a halogen; Y is oxygen, sulfur, =NR3 or = CHR4 where R3 is hydrogen, cyano, lower alkyl, phenyl, lower alkylsulfonyl, or phenylsulfonyl; and R4 is nitro, phenylsulfonyl, or lower alkylsulfonyl, and their pharmaceutically acceptable salts, are novel and are useful for the suppression of gastric acid secretion in mammals. Compositions for such uses containing the compounds are also disclosed. The compounds are made by introducing the of formula group into an amine

  式中的咪唑氰基胍 式中 R1 是氢或甲基 R2为低级烷基；m和n各自独立地为0、1、2或3； A 是苯基、环己烯基、噻吩基、四氢噻吩基或 1，3-二噻吩基，可任选被卤素取代； Y 是氧、硫、＝NR3 或＝CHR4，其中 R3 是氢、氰基、低级烷基、苯基、低级烷基磺酰基或苯基磺酰基；以及 R4 是硝基、苯磺酰基或低级烷基磺酰基，以及它们的药学上可接受的盐，都是新型的，可用于抑制哺乳动物的胃酸分泌。此外，还公开了含有这些化合物的此类用途的组合物。这些化合物是通过将式 基团引入胺
• 苯并吡喃酮类化合物、其制备方法及其应用
  申请人：[en]CHENGDU DI'AO JIUHONG PHARMACEUTICAL FACTORY;[zh]成都地奥九泓制药厂

  公开号：WO2024114765A1

  公开（公告）日：2024-06-06

  本发明提供了一种式(I)所示的苯并吡喃酮类化合物或其药学上可接受的盐、制备方法和用途。该类化合物对POLRMT具有良好抑制作用，可用于治疗和/或预防由POLRMT介导的癌症等疾病。
• Villa; Taddei; Ferri, Farmaco, Edizione Scientifica, 1974, vol. 29, # 1, p. 73 - 79
  作者：Villa、Taddei、Ferri

  DOI：——

  日期：——